Silo Pharma已正式与全球临床研究机构Allucent达成合作意向,双方签署具有战略意义的意向书,旨在加速其创新药物SPC-15的一期临床试验进程。这一关键举措标志着该药物从临床前研究迈向人体试验的重要转折,为后续治疗方案的开发奠定基础。通过整合Allucent在临床试验设计与管理领域的专业资源,Silo Pharma将系统评估SPC-15的安全性与耐受性,推动其神经精神疾病治疗管线的实质性进展。
Silo Pharma已正式与全球临床研究机构Allucent达成合作意向,双方签署具有战略意义的意向书,旨在加速其创新药物SPC-15的一期临床试验进程。这一关键举措标志着该药物从临床前研究迈向人体试验的重要转折,为后续治疗方案的开发奠定基础。通过整合Allucent在临床试验设计与管理领域的专业资源,Silo Pharma将系统评估SPC-15的安全性与耐受性,推动其神经精神疾病治疗管线的实质性进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.